<DOC>
	<DOCNO>NCT00734539</DOCNO>
	<brief_summary>The common etiology infection-related death neurodevelopmental impairment neonate birthweight &lt; 750 g invasive candidiasis . Over 70 % premature neonates develop invasive candidiasis die suffer severe , permanent neurologic impairment . Fluconazole commonly use off-label neonatal intensive care unit , definitive recommendation use nursery hamper limited number well-designed trial . In neonate weigh &lt; 750 g , appropriate dose know , definitive safety long-term follow trial complete , well-powered trial conduct establish efficacy product use mortality part primary endpoint . Three recent proof-of-concept study suggest fluconazole safe effective , recently complete pharmacokinetic study provide data give preliminary dosing guidance . The next logical step drug development propose research : conduct pivotal trial determine safety efficacy fluconazole premature neonates 2-year neurodevelopmental follow-up assessment . 362 neonate , birthweight &lt; 750g , randomize 33 US center , twice weekly fluconazole ( 6 mg/kg ) placebo first 6 week life . The primary efficacy endpoint Candida-free survival study day 49 . The research establish definitive dosing , safety , efficacy fluconazole ; also provide critical information effect fluconazole neurodevelopmental impairment antifungal resistance . Potential Impact : Approximately 17,000 neonate bear &lt; 750 gram year United States . Over 5000 die develop invasive Candida infection . Demonstrating safety efficacy fluconazole preterm neonate improve survivability long term outcomes neonates .</brief_summary>
	<brief_title>Fluconazole Prophylaxis Prevention Candidiasis Infants Less Than 750 Grams Birthweight</brief_title>
	<detailed_description>362 subject randomize study 33 US site . Final study visit Month 18-22 correct age long term follow complete . Study database lock .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Informed consent legally authorize representative . &gt; 48 hour age &lt; 120 hour old time first drug administration &lt; 750 g birth weight Negative blood culture Candida History hypersensitivity severe vasomotor reaction azole receive antifungal therapy suspected/proven invasive fungal infection medical condition , opinion Investigator , may create unacceptable additional risk diagnose invasive candidiasis congenital Candida infection . liver failure ( AST ALT &gt; 250 U/L ) renal failure ( creatinine &gt; 2 mg/dL ) major lethal congenital genetic anomaly triplet high multiple gestation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Days</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Candida</keyword>
	<keyword>Neonate</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Colonization</keyword>
	<keyword>Resistance</keyword>
</DOC>